Aprepitant Effects on Oxycodone Response

Completed · Not applicable · Has a placebo group

Conditions studied: Narcotic Abuse

In brief

Addressing the issue of opioid dependence and tolerance has public health implications for the treatment of opioid abuse (both heroin as well as pharmaceutical opioids) and for the treatment of pain. Recent preclinical data suggest a role for Substance P (NK-1) receptors in modulating both the acute and chronic response to opioids. The objective of this study is to determine whether pretreatment with aprepitant, a selective neurokinin-1 (NK-1) antagonist can reduce the direct response to an opioid agonist (oxycodone) on measures related to abuse liability and reinforcing effects.

Key facts

Study ID

NCT00999544

Run by

Sharon Walsh

People needed

9

Starts

2009-10-01

Expected to finish

2011-04-01

Last updated by the study team

2017-09-01

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Recreational user of opioids
• Healthy
• Ages 18-55 years old
• Able to provide informed consent

You may not qualify if…

• Ongoing medical or psychiatric condition that would be contraindicated for participation
• Past 30 day use of and P4503A4 inhibitor

Where it is running

• University of Kentucky — Lexington, Kentucky, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.